 |
 |
 |
||
    |
||||
 |
||||
|
||||
Doubts on suicide-anti-smoking drug Chantix link
|
Reuters Health
Friday, October 2, 2009
NEW YORK (Reuters Health) - Despite earlier health agency warnings, there is no strong evidence that the anti-smoking drug Chantix raises the risk of suicidal thoughts or depression compared to other stop-smoking products, researchers reported Thursday in the British Medical Journal.
Back in July of this year, U.S. health officials ordered strong "black box" warnings be added to Chantix (also called varenicline) as well as anti-smoking drug Zyban, following more than five thousand reports of depression, hostility and other behavioral changes possibly associated with use of these drugs.
"There have been recent concerns that varenicline, a relatively new smoking cessation product, may increase the risk of suicidal behavior and suicide," study co-author Dr. David Gunnell of the University of Bristol, UK, explained in an email to Reuters Health.
"We found no clear evidence of an increased risk of self-harm or depression associated with varenicline," he said.
The findings stem from data on more than 80,660 would-be quitters in the UK who used different smoking cessation products between September 2006 and May 2008.
A total of 63,265 of these individuals used nicotine replacement products, 10,973 used Chantix, and 6,422 used Zyban, an antidepressant also called bupropion, which has been found to help smokers quit.
When researchers looked at medical records, they didn't find any evidence of an increased risk of serious mental health problems (i.e., self-harm, suicidal thoughts or depression) while they were using these products and during the three months after the last prescription was filled.
Gunnell cautioned, however, that based on the size of the study, it's still possible that Chantix does increase the risk of suicide - or even decrease it.
"Other studies should be undertaken to provide further evidence on this issue," he concluded.
The study was funded by a grant from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).
SOURCE: British Medical Journal, online October 2, 2009.
Reuters Health
© 2009 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies. For additional information on other Reuters media services please visit http://about.reuters.com/media/.
Related News:
More News on this Date
Related MedlinePlus Pages:
| Home | Health Topics | Drugs & Supplements | Encyclopedia | Dictionary | News | Directories | Other Resources | |
| Disclaimers | Copyright | Privacy | Accessibility | Quality Guidelines U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health | Department of Health & Human Services |
Date last updated: 05 October 2009 |